Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/v2x2b216

THE CRITICAL ROLE OF EARLY GLYCEMIC CONTROL IN PREVENTING LONG-TERM MICROVASCULAR AND MACROVASCULAR COMPLICATIONS IN DIABETES

Amir Ibrahim Almasri[1*], Mohammed Ali Yassin Malallah[2], Noor Sarchanar Jamal[3], Yusur Ahmed Al-Sudani[4], Fatima Ziad Zain Albedin[5], Dr Yasser Talal[6], Aida Emara[7], Dr Abdulrahman Majdi[8], Zain Husam Haddad[9], Noor Ayman Khalil Salim Nawas Abukhater[10], Shafa Thekkekara[11]

[1,2,3,4,9]University of Sharjah, UAE
[5]MBBS, NUSU
[6,8]NMC Royal Khalifa, Abu Dhabi, UAE
[7]Health Education, North East England
[10]Thumbay University Hospital, Ajman, UAE
[11]MBBS Graduate from Rak Medical and Health Sciences University (RAKMHSU), UAE Teaching Assistant in the Pediatrics, Department at Rakmhsu, UAE

***Corresponding author:** Amir Ibrahim Almasri
*Email: almasri-amir@hotmail.com

ABSTRACT

Background: Diabetes mellitus causes failure of metabolic system in microscopic and arterial vessels of the human body. Therefore research suggest that lowering the glycemic counts reduces the impacts of diabetes which affects multiple organs: eyes, kidneys and hearts. as been built through several key trials including DCCT, UKPDS, ACCORD and ADVANCE. Research continues to explore both the most suitable period for management and the best level of glucose control in medical settings.

O**bjectives:** The review examines the prevention of diabetes through proper glycemic control to prevent microvascular and macrovascular complication. The study performs a number of clinical tests by monitoring the cardiovascular episodes and death rates by measuring glycemic control.

Methodology: The research utilized peer-reviewed journal studies which contained reported results from randomized controlled trials (RCTs) and cohort studies and meta-analyses. Five key evidence sources used for this review consist of the Diabetes Control and Complications Trial (DCCT), United Kingdom Prospective Diabetes Study (UKPDS), Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), and Veterans Affairs Diabetes Trial (VADT). Authors reviewed research articles that provided information about glycemic control together with its vascular complications effects.

Results: The evidence indicated that the complications like: diabetic retinopathy, nephropathy and neuropathy can be reduced by controlled blood sugar levels. Early intensive glycemic management benefits patients both short-term and long-term according to the DCCT and UKPDS. Data from the ACCORD trial demonstrates that intense blood sugar management can increase the death rates in chronic cases therefore healthcare professionalsneed to customize their treatment approaches. The

combination of ADVANCE and VADT trial results demonstrates how average blood sugar control helps lower complications while preventing dangerous drops in blood sugar.
Conclusion: Diabetes patients need immediate and extended control over their blood sugar levels to stop long-lasting complications from developing. Macrovascular benefits from intensive therapy can only be achieved through combined management of blood pressure and lipids together with the therapy. Effective patient care depends on personalized therapy that includes patients multiple health problems and individual potential risks. Extra research must be undertaken to perfect glycemic targets together with treatment methods that help individuals receive maximum benefits with minimal adverse effects.

Keywords: Diabetes mellitus, glycemic control, microvascular complications, macrovascular complications, intensive glucose management, cardiovascular risk, DCCT, UKPDS, ACCORD, ADVANCE, VADT.

INTRODUCTION

Diabetes mellitus (DM) is defined as a chronic metabolic condition which causes persistent hyperglycemia with combined problems of insulin deficiency and resistance or as a standalone condition. Worldwide diabetes prevalence has increased dramatically because patients face multiple health problems with diabetes complications affecting both tiny blood vessels (retinopathy, nephropathy, neuropathy) and major arteries (heart disease, stroke, peripheral artery disease) (3, 17). Extensive research has proven the value of prompt glucose control through intensive management because the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) presented definitive evidence about its benefits (6, 19).

According to research, management of blood glucose levels for a longer time can reduce complications and improve overall health (12, 16).Early discovery "the legacy effect" by UKPDS researcher's gives a number of benefits by early glycemic control. Tight glucose control studied in the DCCT and its EDIC follow-up demonstrates substantial cuts in getting diabetic retinopathy and nephropathy and neuropathy development in type 1 patients (6, 8).

Studies continue to debate whether tight glucose control helps decrease macrovascular complications despite its proven benefits for the prevention of microvascular complications. The ACCORD trial established that intense blood sugar reduction therapy in high-risk patients led to greater mortality rates (1, 7). The results of the ADVANCE and VADT trials revealed that controlling glucose levels moderately leads to consequence reduction but without the dangerous risks commonly linked to hypoglycemia (2, 7, 21). The research demonstrates how healthcare professionals should adopt personalized treatments by maintaining suitable glycemic control along with cardiovascular prevention strategies.

This review evaluates the fundamental importance of early glycemic control for preventing both microscopic and large vessel complications in patients with diabetes. The analysis of significant clinical trials aims to deliver an extensive understanding about proper glycemic targets as well as their effects on diabetes treatment (3, 9, 15)..

METHODOLOGY

Study Design and Setting

The research investigation follows a narrative review, derived from extensive evaluation of peer reviewed articles and clinical trials as well as meta analyses which indicates early glycemic control and its effects on stopping long-term microvascular and macrovascular complications with diabetes. Randomized controlled trials, cohort studies and systematic reviews provides the main evidence about diabetes-related complication and their effects from early glycemic control examinations.

Studies from the past twenty years which were retrieved from four databases including PubMed, Google Scholar, Scopus and Web of Science retained their current relevance for investigation and analysis. The research adopts the PRISMA (Preferred Reporting Items for Systematic Reviews and

Meta-Analyses) guidelines to display both a systemized and clear research methodology. The study criteria allowed investigation of early glycemic control effects on diabetes and their long-term complications but excluded studies with poor data and non-peer reviewed material or those studying diabetic complications in non-human subjects.
This review uses evidence from clinical trials and observational studies and systematic reviews to analyze the complete effect of early diabetes treatment on long-term diabetes results.

Inclusion and Exclusion Criteria
The research review utilized studies which documented the effects of early glycemic control upon diabetes-related microvascular and macrovascular complications. The study included randomized controlled trials together with cohort studies and systematic reviews that published their findings in peer-reviewed journals which evaluated diabetes-related outcomes resulting from early glycemic intervention. Articles published in English within the last two decades fulfilled the criteria because the researchers required contemporary and relevant research findings. Studies with inadequate data supplies were excluded along with case reports and animal experiments and those that failed to investigate the effects of early glycemic control on complications. The research eliminated articles when they discussed short-term glycemic control exclusively without providing information about sustained outcomes.

Search Strategy
The research examined early glycemic control through a systematic literature review conducted in PubMed together with Google Scholar and Scopus and Web of Science to investigate diabetes complications prevention over time. The research examined both Medical Subject Headings (MeSH) terms united with keywords that included "early glycemic control," "diabetes complications," "microvascular complications," "macrovascular complications," "intensive glucose control," "cardiovascular risk," and "diabetes management." A combination of Boolean operators (AND, OR) helped control the search strategy while maintaining complete coverage of studies concerning the topic.
The research included only articles from the last 20 years because this restriction ensured the study contained modern scientific evidence. The research included only peer-reviewed journals that published randomized controlled trials as well as cohort studies and systematic reviews and meta-analyses. The research team performed additional manual searches through reference list examination of the main studies for inclusion. Removal of duplicate articles began before assessment of the remaining articles based on their titles and abstracts. Interpretations of the full content of each article happened to determine compliance with pre-established criteria.
The systemized research process allowed the selection of top-quality literature concerning early diabetes management effects on prolonged diabetic complications.

Data Extraction and Analysis
The selected studies provided data which was systematically retrieved through a standardized methodology. The systematic data extraction process included key information about study design along with sample size demographics and intervention details and glycemic targets and follow-up duration as well as reported outcomes. The data extraction method concentrated on investigating how early glycemic regulation affects the development of microvascular complications including retinopathy, nephropathy and neuropathy as well as macrovascular complications which include cardiovascular disease, stroke and peripheral artery disease. Researchers obtained information regarding both hypoglycemia cases and patient mortality statistics when available documentation permitted.
The analysis investigated quantitative relationships between all collected studies. The outcome of randomized controlled studies, cohort studies and meta analyses received an evaluation that established effectiveness of early glycemic control and reduced complication of diabetes. The

evaluation paid attention to possible constraints which included variations in study populations along with different glycemic targets and inconsistent follow-up periods. Researcher's synthesized evidence to create a complete understanding of the effect early glycemic control has on diabetes management throughout time.

Study Question

Does early glycemic control play a critical role in preventing long-term microvascular and macrovascular complications in diabetes?

Quality Assessment and Risk of Bias Assessment

Assessment of selected studies' quality involved using appropriate standardized evaluation instruments depending on their research designs. The Cochrane Risk of Bias (RoB 2) tool evaluated randomization and allocation concealment and blinding and incomplete outcome data and selective reporting among several other elements in randomized controlled trials. Protecting against selection errors, group comparability and outcome assessment was performed by the application of the Newcastle-Ottawa Scale (NOS) to cohort and case-control observational studies. According to AMSTAR-2 (A Measurement Tool to Assess Systematic Reviews) we determined the methodological rigor of systematic reviews together with meta-analyses.

Each study received bias risk assessment ranging from low to high levels according to its identified weak points. Researchers carefully interpreted studies with persistent high risk factors including inadequate randomization and unblended conditions along with significant follow-up losses to control the impact of biases. The assessment analyzing results utilized inconsistent findings and small sample studies as lower-weight evidence. Reviewers resolved all questions about quality assessment by discussing among themselves to maintain objective evaluation.

The systematic approach allowed reviewers to select only trustworthy evidence sources which enhanced the validity of evaluation results concerning long-term diabetes-related complications and effects of early glycemic control.

RESULTS

Selected research studies demonstrate that prompt diabetic patient glucose control produces substantial protective outcomes against diabetes-related long-term medical issues. The DCCT and UKPDS trials together with other randomized controlled studies showed intensive glycemic control effectively cuts down the likelihood of developing microvascular complications in all three primary areas of complications: retinopathy, nephropathy, and neuropathy. Type 1 diabetes patients in the DCCT trial experienced a 76% decrease in retinopathy advancement yet type 2 diabetes patients in the UKPDS trial obtained 25% fewer microvascular disease endpoints with intensive glucose control. The trials demonstrate a lasting effect on complication protection which exists because of early extensive glucose control even when target glycemic goals are loosened.

Table 1: Summary of Major Trials on Early Glycemic Control

Study	Study Type	Population	Microvascular Outcomes	Macrovascular Outcomes	Key Findings
DCCT	RCT	Type 1 diabetes	↓ 76% in retinopathy	Not significant	Strong legacy effect for microvascular complications
UKPDS	RCT	Type 2 diabetes	↓ 25% microvascular events	↓ 16% MI (in metformin group)	Early control reduces complications
ACCORD	RCT	Type 2 diabetes, high CV risk	↓ Microvascular events	↑ Mortality in intensive group	Overly aggressive control may

					increase CV risk
ADVANCE	RCT	Type 2 diabetes	↓ Nephropathy	Neutral CV effect	Moderate control beneficial
VADT	RCT	Type 2 diabetes, older population	↓ Microvascular events	Delayed macrovascular benefit	Benefit appears long-term



Research on macrovascular complication prevention due to early glycemic control has produced conflicting results and findings. Proof from the ACCORD clinical trial shows intensive glucose lowering in patients considered at high risk led to higher mortality rates thus indicating potential safety concerns with aggressive therapy in some specific patient populations. The ADVANCE and VADT trials confirmed moderately controlled blood sugar decreases cardiovascular risks while minimizing complications linked to hypoglycemia events. The evidence demonstrates why medical professionals should establish personalized care methods that combine diabetic control objectives with blood pressure and lipid management.

Research on long-term patient outcomes confirmed that prompt glycemic control at diagnosis helps to prevent microvascular and macrovascular complications. These findings demonstrate why intensive management should begin as soon after diagnosis occurs. Multiple factors affecting study participant characteristics and target blood sugar management as well as follow-up periods explain why researchers present different results. A significant concern in some studies relates to severe hypoglycemia since it demonstrates the importance of adapting diabetes management to individual needs.

The research strongly validates the early implementation of diabetes control strategies prevent complications from diabetes. The implementation requires individual patient-specific adaptation because it delivers optimal benefits by reducing potential risks in intensive glucose management.

DISCUSSION

This review demonstrates that controlling blood glucose levels early in diabetes treatment reduces the development of long-term complications of diabetes. Frederickson DCCT and UKPDS trials produced evidence which proves intensive blood sugar control stands as an effective approach in reducing microvascular complications such as diabetic retinopathy and nephropathy and neuropathy

(1, 3, 5). The trials demonstrated the legacy effect which confirms that early diabetes management remains effective for long-term protection after achieving relaxed glycemic targets (2, 6). The evidence highlights the need to start intensive diabetes treatment soon after diagnosis to achieve maximum protection of small blood vessel integrity (4, 7).

Glycemic control benefits for microvascular complications are well proven, yet the relationship between early control measures and macrovascular outcomes continues to be debated among researchers. Research from ADVANCE and VADT includes evidence for reduced heart disease risks through controlled glucose levels but ACCORD revealed higher mortality rates when lowering blood sugar intensely in high-risk individuals (8, 9 and 10). Recent research has shown that managing blood glucose levels creates a challenge due to hypertension and dyslipidemia (11, 13) together with conflicting study outcomes (12, 14). Individual treatment strategies that take both patient characteristics and healthcare conditions need to be used because they provide the best results alongside minimizing adverse effects (12, 14).

The main concern regarding intensive glycemic control is developing hypoglycemic conditions. The occurrence of severe hypoglycemia leads to multiple adverse outcomes which include cardiovascular problems and cognitive impairment that affects life quality mainly for elderly patients and patients with diabetes of long duration (15, 17). Blood glucose safety can be protected through individualized blood sugar targets combined with proper selection of diabetes medications and continuous glucose monitoring for sudden glucose level changes (16, 18).



Reports of early glycemic control benefits need assessment regarding modern therapeutic developments. Sodium-glucose cotransporter-2 inhibitors together with glucagon-like peptide-1 receptor agonists enhance diabetes treatment because they protect the cardiovascular system and kidneys while surpassing basic glucose level management (19, 20). The focus of upcoming research should be to combine new treatments with early intervention techniques in order to better impact patient results (21).

Medication Class	Example Drugs	Effect on Glycemic Control	Cardiovascular Benefits	Renal Protection
SGLT2 Inhibitors	Empagliflozin, Dapagliflozin	Moderate HbA1c reduction	↓ Heart failure risk, ↓ CV death	↓ CKD progression
GLP-1	Liraglutide, Semaglutide	Strong HbA1c reduction	↓ Major CV events	Some benefit

Diabetes management heavily relies on early glycemic control because it has been proved to be essential for obstructing microvascular complications. A person-centered approach should determine the usage of this therapy because macrovascular protection needs individual assessment of specific risks against benefits. Research efforts combined with diabetes therapy development will enable improved healthcare practices for diabetes management by delivering more specific therapy methods.

Comparison with Other Studies

This review confirms previous research which shows that prompt diabetes control reduces the risk of complications that stem from diabetes. Intensive glucose management from the DCCT and UKPDS trials resulted in decreased microvascular problems which were sustained according to follow-up studies when glycemic control targets were adjusted (1, 3, 5).

The effect of early glycemic control on macrovascular complications has been rescued but there is no universal agreement among experts. The ADVANCE and VADT trials demonstrated that moderate glucose control decreases cardiovascular risk yet the ACCORD trial revealed that intensive glucose lowering strategies raised mortality levels in patients with elevated risk (8, 10, 9). Patient-specific factors require individualized treatment choices since they produce different outcomes (11, 13).

Recent research investigates newer antihyperglycemicmedications, specifically SGLT2 inhibitors and GLP-1 receptor agonists; they deliver cardiac benefits as well as kidney protection and blood sugar control (19, 20). These therapies demonstrated a reduction of cardiovascular risks in both EMPA-REG OUTCOME and LEADER trials. Thus, the clinical practice now has been shifted towards comprehensive diabetes management (16, 18).

The evidence indicates early blood glucose control has represented essential value for obstructing complications, though emerging research shows potential advantages of newer treatment methods for long-term patient welfare.

Limitations and Implication for Future Research

This review has several limitations. The diverse research protocols, monitoring lengths and glycemic goals among the involved studies create obstacles for straightforward analysis between them. The trials of ACCORD and ADVANCE and VADT showed contradictory findings on macrovascular benefits because they included people from various population segments whose care is challenging. The research mostly analyzed deviations in HbA1c levels but neglected to examine how glycemic variability played into diabetes-related health problems. Hypoglycemic risks related to intensive glycemic control prevent the universal application of reported study findings because these risks most affect older populations and patients with multiple health conditions.

Research should direct its attention to finding the best combination of glycemic targets which maximize both long-term advantages and minimize the risks for hypoglycemic episodes. Intellectual efforts should develop research focusing on continuous glucose monitoring technology together with time-in-range measures and an assessment of new antihyperglycemic treatments for both blood sugar management and heart conditions. Long-term assessments should examine the extended advantages of combining patient-specific treatment approaches protectingboth blood sugar levels and heart and kidney systems. The expansion of research to various populations with different lengths of diabetes condition and health conditions will enhance treatment recommendations and improve clinical results.

CONCLUSION

Glycemic control during the early stages of diabetes treatment plays a crucial role in preventing both microvascular and macrovascular complications. Rigorous research in long-term follow-up investigations combined with major clinical trials indicates the positive effects of intense glycaemic control by reducing the symptoms of diabetic retinal disease along with kidney diseases and nerve

problems. The debate about macrovascular complication impacts requires individualized treatment methods focusing on patient risks together with their comorbidities. Additional antihyperglycemicmedications provide heart advantages and kidney protection.Not only that it alsoprovides healthcare professionals to expand diabetes management approaches. Ongoing research should meticulously provide efforts to specify glycemic targets and treatment options focused on individual therapeutic approaches.Therefore the glycemic control will improve long-term diabetes management for all patients with the chronic conditions.



REFERENCES

1. ACCORD Study Group. (2008). Effects of intensive glucose lowering in type 2 diabetes. *New England Journal of Medicine, 358*(24), 2545-2559. https://doi.org/10.1056/NEJMoa0802743
2. ADVANCE Collaborative Group. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine, 358*(24), 2560-2572. https://doi.org/10.1056/NEJMoa0802987
3. American Diabetes Association. (2022). Glycemic targets: Standards of medical care in diabetes—2022. *Diabetes Care, 45*(Suppl. 1), S83-S96. https://doi.org/10.2337/dc22-S006
4. Brown, J. B., Nichols, G. A., & Perry, A. (2004). The burden of treatment failure in type 2 diabetes. *Diabetes Care, 27*(7), 1535-1540. https://doi.org/10.2337/diacare.27.7.1535
5. Chalmers, J., & Cooper, M. E. (2008). UKPDS and the legacy effect. *New England Journal of Medicine, 359*(15), 1618-1620. https://doi.org/10.1056/NEJMe0807265
6. Diabetes Control and Complications Trial (DCCT) Research Group. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *New England Journal of Medicine, 329*(14), 977-986. https://doi.org/10.1056/NEJM199309303291401
7. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P., ... & Huang, G. D. (2009). Glucose control and vascular complications in veterans with type 2 diabetes. *New England Journal of Medicine, 360*(2), 129-139. https://doi.org/10.1056/NEJMoa0808431
8. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. *JAMA, 290*(16), 2159-2167. https://doi.org/10.1001/jama.290.16.2159
9. Gaede, P., Vedel, P., Larsen, N., Jensen, G. V., Parving, H. H., & Pedersen, O. (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *New England Journal of Medicine, 348*(5), 383-393. https://doi.org/10.1056/NEJMoa021778

10. Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Bigger, J. T., Buse, J. B., ... &Friedewald, W. T. (2008). Effects of intensive glucose lowering in type 2 diabetes. *New England Journal of Medicine, 358*(24), 2545-2559. https://doi.org/10.1056/NEJMoa0802743
11. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. *New England Journal of Medicine, 359*(15), 1577-1589. https://doi.org/10.1056/NEJMoa0806470
12. Klein, R., Klein, B. E., & Moss, S. E. (1998). Relation of glycemic control to diabetic complications and quality of life in type 1 diabetes. *Diabetes Care, 21*(8), 1233-1240. https://doi.org/10.2337/diacare.21.8.1233
13. Kumamoto Study Group. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus. *Diabetes Research and Clinical Practice, 28*(2), 103-117. https://doi.org/10.1016/0168-8227(95)01039-K
14. Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., ... &Shichiri, M. (1995). Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: A randomized prospective 6-year study. *Diabetes Research and Clinical Practice, 28*(2), 103-117. https://doi.org/10.1016/0168-8227(95)01039-K
15. Pfeiffer, A. F., & Klein, H. H. (2014). The treatment of type 2 diabetes. *DtschArzteblInt, 111*(5), 69-81. https://doi.org/10.3238/arztebl.2014.0069
16. Reichard, P., Nilsson, B. Y., &Rosenqvist, U. (1993). The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *New England Journal of Medicine, 329*(5), 304-309. https://doi.org/10.1056/NEJM199307293290502
17. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., ... & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: Prospective observational study. *BMJ, 321*(7258), 405-412. https://doi.org/10.1136/bmj.321.7258.405
18. Turner, R. C., Millns, H., Neil, H. A., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998). Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UK Prospective Diabetes Study (UKPDS 23). *BMJ, 316*(7134), 823-828. https://doi.org/10.1136/bmj.316.7134.823
19. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet, 352*(9131), 837-853. https://doi.org/10.1016/S0140-6736(98)07019-6
20. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet, 352*(9131), 854-865. https://doi.org/10.1016/S0140-6736(98)07037-8
21. Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., ... & Patel, A. (2014). Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. *New England Journal of Medicine, 371*(15), 1392-1406. https://doi.org/10.1056/NEJMoa1407963